Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Abivax SA Sponsored ADR (NASDAQ:ABVX) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $135.0833.

A number of analysts recently commented on the stock. Citigroup reiterated a “market outperform” rating on shares of Abivax in a research note on Thursday, January 8th. Citizens Jmp raised their price target on shares of Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a report on Tuesday, December 16th. Wall Street Zen downgraded shares of Abivax from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a report on Wednesday, January 21st. Finally, Truist Financial set a $140.00 target price on Abivax in a research note on Monday, November 24th.

Abivax Price Performance

Shares of ABVX stock opened at $117.67 on Friday. The stock’s 50-day moving average is $122.06 and its 200 day moving average is $100.30. Abivax has a 1-year low of $4.77 and a 1-year high of $148.83. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86. The company has a market cap of $9.23 billion, a P/E ratio of -28.15 and a beta of 0.79.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The firm had revenue of ($4.92) million for the quarter. Research analysts predict that Abivax will post -2.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Abivax

Several hedge funds and other institutional investors have recently bought and sold shares of ABVX. Legato Capital Management LLC boosted its position in Abivax by 316.9% in the 4th quarter. Legato Capital Management LLC now owns 10,648 shares of the company’s stock worth $1,436,000 after purchasing an additional 8,094 shares in the last quarter. Global Retirement Partners LLC increased its holdings in shares of Abivax by 2,368.0% during the 4th quarter. Global Retirement Partners LLC now owns 1,234 shares of the company’s stock valued at $166,000 after purchasing an additional 1,184 shares in the last quarter. Atle Fund Management AB acquired a new position in shares of Abivax in the 4th quarter valued at $4,260,000. PNC Financial Services Group Inc. lifted its stake in shares of Abivax by 2,201.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,245 shares of the company’s stock valued at $438,000 after purchasing an additional 3,104 shares during the period. Finally, TimesSquare Capital Management LLC boosted its holdings in Abivax by 1.1% during the fourth quarter. TimesSquare Capital Management LLC now owns 129,384 shares of the company’s stock worth $17,448,000 after buying an additional 1,361 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.